Competitive Advantages
- Potentially more effective than current treatments
- Less toxic than current treatments
- Treats a variety of bacterial pathogens
- Compound can be administered in a variety of delivery methods
Summary
Heat Shock Protein 90 (Hsp90) is known to be a highly conserved protein amongst these bacterial pathogens and is involved in a variety of morphological processes. Inhibiting Hsp90 is therefore recognized as a potential therapeutic target for the treatment of these pathogens. USF inventors have developed a series of novel Hsp90 inhibitors that they have shown to be effective against Leishmania donovani and ESKAPE pathogens. This development has the potential to provide a new more effective treatment that is also less toxic than the current gold standard treatments.
Heat Shock Protein Inhibitor Compound Docked in Active Site of Hsp90
Desired Partnerships
- License
- Sponsored Research
- Co-development